University of Colorado Cancer Center | Strategic Alliance Partners

Latest from University of Colorado Cancer Center


Published Entrectinib Data Demonstrate Encouraging Responses in ROS1+ NSCLC

December 16, 2019

Treatment with entrectinib led to an overall response rate of 77% and a median duration of response of 24.6 months in patients with ROS1 fusion–positive non–small cell lung cancer, according to updated findings of a pooled analysis published in Lancet Oncology.

Brigatinib Maintains PFS Benefit in Frontline ALK+ NSCLC at Long-Term Follow-Up

November 25, 2019

Treatment with brigatinib demonstrated a 57% reduction in the risk of disease progression or death compared with crizotinib in patients with advanced ALK-positive non–small cell lung cancer who had not received a prior ALK inhibitor.

Dr. Lieu Discusses the Focus of Future Research in mCRC

September 12, 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses where future research should focus in metastatic colorectal cancer.

Dr. Davis on Immunotherapy in HER2-Positive Gastric/GEJ Cancer

September 04, 2019

S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses an investigational immunotherapy combination being explored in patients with HER2-positive gastric and gastroesophageal junction (GEJ) cancer.

Dr. Davis on the Role of Ramucirumab in Gastric/GEJ Cancer

August 20, 2019

S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses the role of ramucirumab (Cyramza) in the treatment of patients with gastric/gastroesophageal junction (GEJ) adenocarcinoma.

Dr. Lieu Discusses the Rationale for Combined MEK/VEGF/PD-1 Inhibition in CRC

August 08, 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses the rationale for combined MEK, VEGF, and PD-1 inhibition in microsatellite stable (MSS) colorectal cancer (CRC).

Dr. Lieu on the Predictive Value of BRAF V600E Mutations in mCRC

July 26, 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associate director for clinical research, at the University of Colorado Cancer Center, discusses the predictive value of BRAF V600E mutations in metastatic colorectal cancer (mCRC).

Dr. Lieu on Investigational Immunotherapy Strategies in mCRC

July 02, 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associate director for clinical research, at the University of Colorado Cancer Center, discusses investigational immunotherapy strategies in metastatic colorectal cancer (mCRC).

Dr. Davis on Caveats of the KEYNOTE-062 Trial Findings in Gastric/GEJ Cancer

June 25, 2019

S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses caveats of the phase III KEYNOTE-062 trial findings in gastric and gastroesophageal junction (GEJ) cancer.

Dr. Lieu on HER2-Directed Therapy in CRC

June 14, 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses HER2-directed therapy for patients with colorectal cancer (CRC).